Evidence map›Paper›PMID 39325987›Full record

ArticleHematological oncology2024

Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35).

Maria Cristina Pirosa, Sara Steffanoni, Anna Vanazzi, Fabiana Esposito, Angela Polino, Alberto Schena, Francesco Landi, Maria Elena Cabrera, Saad Akhtar, Santiago Gardella and 4 more

Abstract read
In one paragraph

Article in Hematological oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maria Cristina PirosaOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.ORCID https://orcid.org/0000-0001-5277-9835
Sara SteffanoniValduce Hospital, Como, Italy.ORCID https://orcid.org/0000-0002-6314-0241
Anna VanazziHemato-Oncology Division, Istituto Europeo di Oncologia, Milan, Italy.
Fabiana EspositoOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Angela PolinoOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Alberto SchenaOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Francesco LandiOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Maria Elena CabreraMedicine Service, Hematology Section, Hospital del Salvador, University of Chile, Santiago, Chile.ORCID https://orcid.org/0000-0001-9059-3871
Saad AkhtarKing Faisal Specialist Hospital and Research Centre, King Abdullah Center for Oncology and Liver Disease, Riyadh, Saudi Arabia.
Santiago GardellaInstitut Catala d'Oncologia, Girona, Spain.
Osnat BaireyDavidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.
Astrid PavlovskyFundaleu-Fundación Para Combatir la Leucemia, Buenos Aires, Argentina.
Anastasios StathisOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Emanuele ZuccaOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.ORCID https://orcid.org/0000-0002-5522-6109

Funding

Swiss Cancer Research Foundation
6 · The paper itself

Abstract

Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT between 1982 and 2012. The median age was 52 years. Limited stage, as defined by the Ann Arbor and FIGO staging systems, was observed in 55% and 63% of cases, respectively. The uterus was the primary site of lymphoma in 25 cases, with the ovaries as the second most common site (n = 24). The most common histological subtype was diffuse large B-cell lymphoma (DLBCL, n = 44), followed by follicular lymphoma and marginal zone lymphoma (6 patients each). Two patients received surgery alone as first-line therapy, while 58 underwent systemic therapy, 16 following major surgery. Thirteen patients received consolidation radiotherapy and six were given central nervous system (CNS) prophylaxis. Twenty patients had disease progression or recurrence. Six patients with DLBCL (14%) experienced CNS relapse, which was the only site of recurrence in five of them. All but one patient with CNS relapse had primary ovarian involvement, and three had bulky disease; none of these patients had received CNS prophylaxis. With a median follow-up of 60 months, the median overall survival of the DLBCL cohort was approximately 13 years, with a 5-year survival rate of 77%. In multivariable analysis, advanced disease according to the FIGO system was the only parameter significantly associated with shorter overall, cause-specific, and progression-free survival in patients with DLBCL.

Indexed as

Genital Neoplasms, FemaleNeoplasm StagingAdolescentAdultAgedAged, 80 and overFemaleHumansLymphoma, Large B-Cell, DiffuseMiddle AgedPrognosisRetrospective StudiesSurvival RateYoung AdultchemotherapyCNS prophylaxisfemale reproductive systemlymphoma

Identifiers

PMID39325987
PMCPMC11590041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.